News

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharmaceutical company, today announced a research collaboration with the goal to accelerate the development of innovative treatments for autoimmune diseases.

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO, Peter Nestorov, will present at the Precision Medicine and the Future of Genomics Summit in Doha, Qatar. The summit will bring together global experts to shape the future of healthcare in the Middle East and beyond.

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of immunotherapy research, focusing on the underestimated role of type 2 T cell immunity in cancer. Leveraging single-cell multi-omics, these studies illuminate how type 2 immunity, often overlooked in conventional paradigms, contributes to durable cancer remission and immune modulation. Together, they represent a paradigm shift in our understanding of T cell biology, underscoring the power of single-cell data to drive unbiased and transformative discoveries.

Global Entrepreneurship Week Basel Nov 21 2024 CEO Peter Nestorov’s (2nd from right) company now employs over 20 people (Photograph: ETH Zurich / Scailyte). Scailyte announces its new advisory board